Raymond James analyst Elliot Wilbur attributed the late afternoon spike in Perrigo shares yesterday to a report from Street Insider suggesting that the company is near a deal to be acquired by an unnamed U.K. company for $20B. There are few U.K. companies capable of pulling off such a transaction, said Wilbur, who remains of the opinion that there are few natural buyers for Perrigo. Mylan (MYL), who is the "closest thing to a natural buyer" of Perrigo, seems increasingly unlikely to bid again for the company given its announced purchase of Meda and recent acquisition of Renaissance, according to the analyst. Longer-term, the Perrigo platform makes the most sense for a large scale U.S. focused generics company, said Wilbur, who keeps a Market Perform rating on the stock.